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Abstract Deoxycytidine kinase (dCK) phosphorylates several
anti-cancer and anti-viral nucleoside analogs. The enzyme is
predominantly expressed in lymphoid tissues regulated by an
unknown mechanism. We have cloned and sequenced the 20 kbp
mouse dCK gene andW1.7 kbp of the 5P flanking regions of both
the human and mouse dCK genes. Five major inter-species
conserved motifs were identified in the 5P region including the
transcription initiation region, an SP1 site and two closely
located putative octamer transcription factor sites. Luciferase
reporter experiments showed that the human dCK 5P region
efficiently initiated transcription but no tissue regulatory element
could be identified. ß 2000 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Human deoxycytidine kinase (dCK) phosphorylates several
clinically important anti-cancer and anti-viral nucleoside ana-
logs such as 1-L-D-arabinofuranosylcytosine and 2-chloro-2P-
deoxyadenosine used in treatment of hematological malignan-
cies and the anti-HIV compounds 2P,3P-dideoxycytidine and
2P-deoxy-3P-thiacytidine [1,2]. The nucleoside analogs are in-
active prodrugs that are dependent on phosphorylation for
pharmacological activity. dCK is constitutively expressed
throughout the cell cycle and low levels of the protein are
present in most tissues investigated [3^6]. dCK is, however,
predominantly expressed in lymphoid cells with particular
high levels in immature T-lymphoblasts [7,8]. The lympho-
blasts are highly sensitive to purine deoxyribonucleosides
and nucleoside analogs phosphorylated by dCK. The high
levels of dCK in these cells have been implicated as the mech-
anism of lymphocyte depletion caused by disorders of purine
metabolism and as a mechanism of tissue targeted cytotoxicity
of dCK phosphorylated anti-leukemic nucleoside analogs
[8,9]. In accordance with this hypothesis, acquired resistance
to nucleoside analogs has been associated with decreased dCK
expression [10,11] or mutation in the coding region of the
dCK gene [12,13].
Parts of the human dCK gene are cloned, and a 0.5 kbp
DNA fragment located upstream of the translation start site
has been investigated for promoter activity [14,15]. The dCK
gene lacks a TATA-box but contains a transcription initiator
region located adjacent to the major transcription start site at
bp 3146 relative to the start of translation. The initiation
region contains an imperfect E2F binding site [14]. The hu-
man dCK promoter has a high GC content similar to several
other TATA-less promoters, and there are at least two SP1
sites that regulate transcription of the gene [15]. Reporter gene
studies on the human dCK promoter show higher levels of
reporter gene activity in T-lymphoblast than in B-lymphoblast
cell lines [14]. However, further studies have failed to show
that the 0.5 kbp region regulates tissue speci¢c transcription
of the human dCK gene [15].
We decided to clone the mouse dCK gene to further study
the transcription regulation of dCK. We report in the present
study the DNA sequencing of the 20 kbp mouse dCK gene
and W1.7 kbp of the 5P £anking regions of both the human
and mouse dCK genes. We have used the sequence informa-
tion to identify sequence conserved motifs that may regulate
transcription of the genes.
2. Materials and methods
2.1. Cloning and sequencing of human and mouse dCK genomic DNA
The open reading frame of the mouse dCK cDNA [17] was labeled
with [K-32P]dCTP (3000 Ci/mmol, Amersham) (Prime-A-Gene, Prom-
ega). 106 plaques of a mouse (strain 129SVJ) liver genomic DNA
library constructed in V-FIXII vector (Stratagene) were replicated
on Colony/Plaques screen membranes (DuPont NEN). Hybridization
was carried out at 42‡C in 4USSC (SSC is 150 mM NaCl, 15 mM
sodium citrate pH 7)/50 mM NaH2PO4/5UDenhardt’s solution (Den-
hardt’s is 0.02% Ficoll/0.02% polyvinylpyrrolidone/0.02% bovine se-
rum albumin)/1% sodium dodecyl sulfate (SDS)/10% dextran sulfate/
20% formamide/50 Wg/Wl denatured salmon sperm DNA. Filters were
washed three times at 42‡C in 2USSC/0.1% SDS for 30 min and
autoradiographed for 24^72 h. Positive plaques were harvested and
re-screened with the cDNA probe to isolate single V clones.
We used the Human Promoter Finder DNA Walking kit (Clontech)
to clone the 5P £anking region of the human dCK gene. Oligonucleo-
tide primers (5P-TGGGCGTAGTTGCTTTTAGAGGTAGCTTCCC
and 5P-CGGTGGGGCGGGTTCTCTTCGAAGGGCA) were de-
signed based on the DNA sequence of the human dCK promoter
[14]. The Expand Long Template PCR system (Boehringer Mann-
heim) was used for the PCR as described in the Clontech protocol.
All DNA sequences were determined with the Automatic Laser Fluo-
rescence DNA sequencer (Pharmacia Biotech Inc.) or the ABI310
automated DNA sequencer (Perkin-Elmer, Applied Biosystems). Pu-
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tative transcription factor binding sites were identi¢ed using the
TransFac data base [16].
2.2. Construction of reporter gene plasmids
An oligonucleotide primer located at bp 322 to 31 in the human
dCK gene with a 5P BamHI restriction enzyme site was common to all
reporter plasmids constructed (5P-CCCGGATCCTTAGTCTT-
GTGGCGGCCCAGA). Oligonucleotide primers at bp 31630,
31000, 3800 or 3550 of the human dCK gene were designed with
KpnI restriction enzyme sites (5P-CTGGTACCATCCGGTTTAT-
TAGTG, 5P-TTTGGTACCTATGTGCCAGGTGTCGG, 5P-ACA-
GGTACCGGTATGGAGACTGGAAAGG, and 5P-GTGGGTACC-
TTAAGTCTATCCAGTTCTGTCC). The PCR-ampli¢ed DNA
fragments were cloned into the BamHI^KpnI sites of the pGL3-basic
plasmid vector. The constructed plasmids were puri¢ed with the midi-
prep kit (Quiagen).
2.3. Cell culture, transfection and reporter gene assays
Molt-4 and Jurkat human T-lymphoblast cells lines were gifts from
Dr. J. Balzarini. The human epitheloid cervical carcinoma cell line
HeLa was obtained from the American Type Culture Collection.
Molt-4 and Jurkat cells were cultured in Eagle RPMI 1940 medium
and HeLa cells were cultured in Dulbecco’s modi¢ed Eagles medium.
All cell culture medium was supplemented with 10% fetal calf serum
(Gibco BRL), 100 U/ml penicillin and 0.1 mg/ml streptomycin. The
cells were transfected with DMRIE-C lipofectin reagent (Gibco) ac-
cording to the Gibco protocol. The cells were harvested 24 h after
transfection and the luciferase activity was determined with the lucif-
erase assay kit (Promega). L-Galactosidase activity was determined
with the L-gal assay kit (Promega).
3. Results
We screened a mouse genomic DNA V library with a mouse
dCK cDNA probe. Five positive V clones were isolated from
the 106 plaques screened. Southern blot analysis with oligo-
nucleotide probes derived from di¡erent parts of the mouse
dCK cDNA sequence were used to con¢rm that the V clones
contained the mouse dCK gene (data not shown). Three of
the ¢ve clones showed unique restriction patterns when the
puri¢ed V DNA was restriction-digested with EcoRI and Hin-
dIII (data not shown). All V clones contained DNA inserts of
W20 kbp. We designed oligonucleotide primers to PCR am-
plify the regions in the mouse dCK gene that corresponded to
the intron regions of the human gene. These experiments
showed that the three unique clones (V-1, V-2 and V-3) covered
the complete coding sequence of the mouse dCK gene as well
as the 5P and 3P £anking regions (Fig. 1). The clones were
sequenced and a complete DNA sequence of 20 250 bp was
obtained, including 1750 bp located upstream of the trans-
lation start codon (GenBank accession number AF260315).
The mouse dCK gene consisted of seven exons and the in-
tron/exon junctions were located at the same positions in both
the human and mouse dCK genes. The DNA sequence that
corresponded to the 5P untranslated region of the mRNA and
the translation initiation codon were located in the ¢rst exon.
The large 3P untranslated region was located in exon seven.
We decided to clone and compare the 5P £anking sequences
of the human and mouse dCK genes to identify inter-species
Fig. 1. Structure of the mouse dCK gene from the isolated V clones (V-1, V-2, V-3). The coding sequence is distributed in seven exons (black
boxes).
Fig. 2. Alignment of the human and mouse dCK gene 5P £anking regions. Five major sequence conserved regions were identi¢ed (A^E). The
transcription start site of the human dCK gene is at bp 3146 (arrow). The numbers indicate the nucleotide positions relative to the translation
start codon.
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sequence conserved regions that might regulate transcription
of the dCK gene. Similar to the human dCK 5P sequence, the
mouse gene had a high GC content and the gene lacked a
TATA-box. The immediate 0.5 kbp region upstream of the
translation initiation codon of the human dCK gene is cloned
and characterized [14,15]. We cloned a larger part of the 5P
£anking sequence of the human dCK gene in order to com-
pare the human DNA sequence with the 1.7 kbp 5P sequence
of the mouse gene. We used a PCR-based method to clone a
1.6 kbp DNA fragment 5P of the human dCK gene (GenBank
accession number AF260316). Alignment of the 5P DNA se-
quences of the human and mouse dCK genes showed ¢ve
major regions at best alignment that were conserved in the
genes of both species (Fig. 2). Region A was located at bp
3150 to 3174 in the human gene and at bp 399 to 3123 in
the mouse gene relative to the translation start codons. The
region was located adjacent to the transcription start of the
human dCK gene and the partial binding site for E2F identi-
¢ed in the human gene was also present in the mouse dCK
gene. Northern blot analysis of mouse dCK mRNA shows
that the mRNA is 3.4 kbp whereas the translated region of
the cloned cDNA and the 3P untranslated region are 2.8 kbp
[17]. Transcription initiation of the mouse dCK gene occurs
accordingly within 0.6 kbp upstream of the translation start,
but the exact position cannot be predicted because the length
of the 3P polyadenylated tail of the mRNA is not known.
However, these data are in accordance with the hypothesis
that transcription of the human and mouse dCK is initiated
at region A.
Region B corresponded to a GC-rich cluster that binds SP1
in the human dCK gene, and reporter gene experiments sug-
gest that the site is important for transcriptional activity of
the human gene [15]. Regions C, D, E are all located upstream
of the previously characterized human dCK promoter and
there is no information available about their importance for
transcription of the dCK gene. We searched the TransFac
data base to identify transcription factor binding sites in the
inter-species conserved regions C, D, and E [16]. The best
matches found were two octamer transcription factor binding
sites in the region D (Fig. 2).
We used luciferase gene reporter assays to study the tran-
scription activating properties of regions C, D and E identi¢ed
in the human and mouse dCK genes. Parts of the human dCK
5P £anking region were inserted upstream of the luciferase
reporter gene (Fig. 3A). The plasmids were transiently trans-
fected into HeLa epithelium carcinoma cells, T-lymphoblast
Molt-4, and Jurkat cells. A plasmid that encoded the L-galac-
tosidase gene was used as a control to monitor the transfec-
tion e⁄ciency. The plasmids that contained the previously
characterized proximal 0.5 kbp fragment of the human dCK
gene (dCK (A+B), Fig. 3A) increased luciferase activity W80-
fold as compared to the negative control (Fig. 3B). Addition
Fig. 3. Reporter gene analysis of the transcription activation by the human dCK gene 5P region. (A) Parts of the human dCK 5P region were
cloned upstream of the luciferase reporter gene. A^E indicate the conserved sequence motifs present in both human and mouse dCK genes (see
Fig. 2). (B) Assays of luciferase activity in crude extracts of human cell lines transfected with the reporter gene plasmids. The level of lumines-
cence is shown in relation to L-galactosidase activity (luc/L-gal). N.D. not determined.
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of regions C, D or E to the reporter gene construct did not
signi¢cantly alter the levels of reporter gene activity as com-
pared to the plasmid that contained only regions A and B in
the investigated cell lines.
4. Discussion
The expression of dCK in normal and malignant cells has
been studied by several groups [1]. Predominant expression of
dCK in lymphoid cells and tissues has been shown both by
enzymatic assays [3,6,7] and by analysis of the levels of dCK
protein with anti-dCK antibodies [5]. Steady-state levels of
dCK mRNA are high in lymphoid tissues, but high levels of
dCK mRNA are also present in muscle and brain [17,18]. This
is in contrast to studies on crude protein extract of human
muscle and brain that contain very low levels of dCK [5,6].
The reason for the discrepancy is not known, but it has been
suggested that expression of dCK may be regulated at the
post-transcriptional level in certain cell types [19]. It is pres-
ently not known whether the lymphoblast predominant ex-
pression of dCK is regulated at the transcriptional or post-
transcriptional level and further studies will be required to
clarify this issue.
We have extended previous studies on the transcriptional
regulation of the dCK gene by cloning 1.7 kbp and 1.6 kbp
regions upstream of the translation start of both the human
and mouse dCK genes. Comparison of the DNA sequences
showed that a sequence motif located adjacent to the tran-
scription start of the human dCK genes was conserved in the
mouse dCK gene. The initiation region binds the E2F tran-
scription factor in vitro [15]. Members of the E2F family may
initiate transcription in other TATA-less promoters such as
the dihydrofolate reductase promoter [20]. However, E2F is
involved in cell cycle regulation and many of its target genes
are di¡erentially expressed in the phases of the cell cycle [20].
The mechanism of E2F-mediated transcription initiation in
cell cycle constitutively expressed genes, such as dCK, is not
known. It is possible that an E2F-like factor is constitutively
expressed and functions as an initiator, similar to the consti-
tutively expressed TATA binding proteins. In addition to the
initiation region, we identi¢ed a SP1 binding site that was
present in the dCK genes of both species. SP1 sites are com-
mon in genes with TATA-less promoters and SP1 has been
suggested to activate transcription in cooperation with the
initiation protein [20]. There is an E-box motif adjacent to
the SP1 site in the human dCK gene [14]. However, we
were not able to identify a similar motif in the mouse dCK
gene and its physiological importance for regulation of dCK
transcription remains unclear. Among the other three regions
that were conserved in the 5P sequences of the human and
mouse dCK genes, one region contained two closely located
imperfect binding sites for octamer transcription factors. Oc-
tamer motifs regulate expression of B-cell speci¢c genes such
as the immunoglobulins [21]. The octamer binding transcrip-
tion factors oct-1 and oct-2 are however present in most he-
mopoietic and lymphoid tissues [22] and the octamer tran-
scription factors are involved in transcription regulation of
T-lymphocyte speci¢c genes [23]. Closely located octamer
sites, such as those found in the dCK gene, allow cooperative
binding of oct-2 proteins [24]. It is tempting to speculate that
the octamer motifs in the dCK 5P region participate in the
regulation of dCK transcription. There is, however, so far no
experimental evidence that either regions C, D, or E are im-
portant for the expression of the dCK gene.
The physiological role of the constitutively expressed deoxy-
ribonucleoside kinases is suggested to be in providing deoxy-
ribonucleotides for DNA repair and replication of mitochon-
drial DNA in resting and terminally di¡erentiated G0 cells,
when the de novo pathway of deoxyribonucleotide synthesis is
not active. This model does, however, not explain why dCK is
predominantly expressed in lymphoid tissues or why very low
levels of the enzyme are present in tissues that mainly consist
of resting or terminally di¡erentiated cells. The cloning and
sequencing of the mouse dCK gene reported in this paper will
be the basis for future studies on the physiological importance
of dCK by gene targeting experiments in transgenic mice.
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